Intrinsic Imaging Awarded Multinational Phase II Trial for the Study of Metastatic Breast Cancer

Share Article

Over the 4 year duration of this clinical trial, Intrinsic Imaging will provide imaging core lab services to manage the acquisition, transfer and processing of medical images from over 60 investigator sites located in 10 countries.

Intrinsic Imaging is proud to contribute its expertise to this very important multinational clinical trial for the benefit of metastatic breast cancer patients.

Todd A. Joron, BSc. MBA, President & COO

Intrinsic Imaging LLC, an ISO 9001:2008 compliant medical imaging core lab providing complete image management and radiological review services to global pharmaceutical, biotechnology and medical device organizations, announces today that it was recently awarded a multinational Phase II clinical trial for the study of metastatic breast cancer.

Over the 4 year duration of this clinical trial, Intrinsic Imaging will provide imaging core lab services to manage the acquisition, transfer and processing of medical images from over 60 investigator sites located in 10 countries. Intrinsic Imaging will also provide its team of oncology subspecialized radiologists for guidance on RECIST interpretation of medical images over the duration of this multinational trial.

“Today, the 5 year survival rate for a woman diagnosed with metastatic breast cancer is less than 15%.” said Todd A. Joron, BSc. MBA, President & COO, Intrinsic Imaging. “With such a prognosis, it is critical that breast cancer trials are conducted in a timely fashion, managed optimally and effectively executed. Intrinsic Imaging is proud to contribute its expertise to this very important multinational clinical trial for the benefit of metastatic breast cancer patients.”

With the exception of skin cancer, Breast cancer is the most common cancer among American women. The American Cancer Society's most recent estimates for breast cancer in the United States project that in 2011 over 230,000 new cases of invasive breast cancer will be diagnosed in women. Of those, nearly half of all patients who are treated for apparently localized breast cancer will develop metastatic disease and most will eventually succumb to their cancer.

“At Intrinsic Imaging, we join the many accredited researchers in this global fight against metastatic breast cancer.” said Amit Mehta, MD., Vice President & Medical Director, Intrinsic Imaging. “We are readily able to provide our wealth of oncology and clinical trial expertise to evaluate new treatment efficacy and/or disease progression.”

In addition to trial management and evaluations related to metastatic breast cancer, Intrinsic Imaging radiologists routinely perform all elements of breast cancer imaging including, but not limited to, Digital Mammography with and without Computer Aided Detection (CAD), Breast Ultrasound, Breast MRI, Breast cancer staging by PET/CT, Nuclear Imaging and Interventional Breast Therapy including Needle localization, MRI guided, ultrasound guided and stereotactic biopsy.

About Intrinsic Imaging LLC
Located in San Antonio, TX and Boston, MA, Intrinsic is an ISO 9001:2008 compliant medical imaging core lab providing complete image management and radiological review services to global pharmaceutical, biotechnology and medical device organizations. With its team of more than sixty sub-specialized, board-certified radiologists, and through its use of advanced medical imaging technology, Intrinsic Imaging experienced clinical trial team provides sponsors with comprehensive imaging core lab services across all therapeutic areas including expert radiologist consultation, protocol design and image charter development, investigator site qualification and training, as well as image acquisition, processing, analysis and data management. For more information, please visit http://www.IntrinsicCRO.com.

RECIST - Response Evaluation Criteria In Solid Tumors

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Todd Joron
Visit website